Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

被引：96

作者：

Cavaletti, Guido ^{[1
]}

Alberti, Paola ^{[1
]}

Marmiroli, Paola ^{[1
]}

机构：

[1] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20900 Monza, Italy

来源：

LANCET ONCOLOGY | 2011年 / 12卷 / 12期

关键词：

GLUTATHIONE-S-TRANSFERASE; METASTATIC COLORECTAL-CANCER; ADVANCED GASTRIC-CANCER; PLACEBO-CONTROLLED TRIAL; CELL LUNG-CANCER; OXALIPLATIN-BASED CHEMOTHERAPY; CISPLATIN-BASED CHEMOTHERAPY; CONTINUOUS VENOUS INFUSION; DRUG-METABOLIZING-ENZYMES; VITAMIN-E SUPPLEMENTATION;

D O I：

10.1016/S1470-2045(11)70131-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to predict response to treatment but also to assess the toxic action of drugs on normal cells (so-called toxicogenomics). This technological progress could enable us to identify individuals at high and low risk for a given side-effect. Pharmacogenomics could be very useful for stratification of cancer patients at risk of developing chemotherapy-induced peripheral neurotoxicity, one of the most severe and potentially permanent non-haematological side-effects of modern chemotherapeutic agents. However, study data reported so far are inconsistent, which suggests that methodological improvement is needed in clinical trials to obtain reliable results in this clinically relevant area.

引用

页码：1151 / 1161

页数：11

共 83 条

[1] Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? [J].

Antonacopoulou, A. G. ;

Argyriou, A. A. ;

Scopa, C. D. ;

Kottorou, A. ;

Kominea, A. ;

Peroukides, S. ;

Kalofonos, H. P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (07) :963-968

[2] A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results [J].

Argyriou, Andreas A. ;

Chroni, Elisabeth ;

Koutras, Angelos ;

Iconomou, Gregoris ;

Papapetropoulos, Spiridon ;

Polychronopoulos, Panagiotis ;

Kalofonos, Haralabos P. .

SUPPORTIVE CARE IN CANCER, 2006, 14 (11) :1134-1140

[3] Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation [J].

Argyriou, Andreas A. ;

Chroni, Elisabeth ;

Koutras, Angelos ;

Iconomou, Gregoris ;

Papapetropoulos, Spiridon ;

Polychronopoulos, Panagiotis ;

Kalofonos, Haralabos P. .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 32 (03) :237-244

[4] Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer [J].

Bergmann, Troels K. ;

Green, Henrik ;

Brasch-Andersen, Charlotte ;

Mirza, Mansoor R. ;

Herrstedt, Jorn ;

Holund, Berit ;

du Bois, Andreas ;

Damkier, Per ;

Vach, Werner ;

Brosen, Kim ;

Peterson, Curt .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (07) :693-700

[5] Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 [J].

Boige, Valerie ;

Mendiboure, Jean ;

Pignon, Jean-Pierre ;

Loriot, Marie-Anne ;

Castaing, Marine ;

Barrois, Michel ;

Malka, David ;

Tregouet, David-Alexandre ;

Bouche, Olivier ;

Le Corre, Delphine ;

Miran, Isabelle ;

Mulot, Claire ;

Ducreux, Michel ;

Beaune, Philippe ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) :2556-2564

[6] Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer [J].

Booten, Richard ;

Ward, Tim ;

Heighway, Jim ;

Ashcroft, Linda ;

Morris, Julie ;

Thatcher, Nicholas .

JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) :679-683

[7] Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial [J].

Broyl, Annemiek ;

Corthals, Sophie L. ;

Jongen, Joost L. M. ;

van der Holt, Bronno ;

Kuiper, Rowan ;

de Knegt, Yvonne ;

van Duin, Mark ;

el Jarari, Laila ;

Bertsch, Uta ;

Lokhorst, Henk M. ;

Durie, Brian G. ;

Goldschmidt, Hartmut ;

Sonneveld, Pieter .

LANCET ONCOLOGY, 2010, 11 (11) :1057-1065

[8] Lessons learned in the assessment of health-related quality of life: Selected examples from the national cancer institute of Canada clinical trials group [J].

Brundage, Michael ;

Osoba, David ;

Bezjak, Andrea ;

Tu, Dongsheng ;

Palmer, Michael ;

Pater, Joseph .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (32) :5078-5081

[9] An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer [J].

Caponigro, F. ;

Lacombe, D. ;

Twelves, C. ;

Bauer, J. ;

Govaerts, A. -S. ;

Marreaub, S. ;

Milano, A. ;

Anthoney, A. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (01) :48-55

[10] Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial [J].

Cascinu, S ;

Catalano, V ;

Cordella, L ;

Labianca, R ;

Giordani, P ;

Baldelli, AM ;

Beretta, GD ;

Ubiali, E ;

Catalano, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3478-3483

← 1 2 3 4 5 6 7 8 9 →